RDOC News - 500 Beiträge pro Seite

[NoFear]

Hi !

Ich habe mal das Neueste zu RDOC (Integrated Surgical Systems) zusammengetragen. Beginnen wir mit den Nachrichten :

published: 27.06.01 14:43
Beweglich wie menschlicher Arm
Roboter operiert menschliches Hirn
Frankfurt/Main (rpo). An einer Frankfurter Unfallklinik haben Neurochirurgen ein menschliches Gehirn mit Hilfe eines neuartigen Roboters operiert. Die bei dem Patienten nach einem Unfall aufgetretenen Hirnblutungen wurden mit einem deutschlandweit einmaligen rechnergestützten Verfahren gestoppt.
Dafür sei nur ein acht Millimeter großes Bohrloch nötig gewesen, berichtete Oberarzt Nils Haberland von der Berufsgenossenschaftlichen Unfallklinik Frankfurt/Main am Mittwoch. Der Eingriff fand bereits am Montag statt.
Der Roboter "NeuroMate" arbeite auf zehntel Millimeter genau und sei mit seinen fünf Gelenken ebenso beweglich wie ein menschlicher Arm. Der Roboter sei präziser als der erfahrenste Operateur, sagte Haberland. "Wir werden ihn auch bei der Behandlung von Hirntumoren und bei Parkinson-Symptomen einsetzen", kündigte der Arzt an. Nach Angaben der Deutschen Gesellschaft für Neurochirurgie sind roboterassistierte Hirnoperationen in Deutschland schon länger üblich.
Ab Herbst will die Frankfurter Unfallklinik mit dem Roboter auch Wirbelsäulen-operationen vornehmen. So könnten beispielsweise Bandscheibenvorfälle behoben werden, ohne die Rückenmuskulatur zu öffnen. An der Klinik wird seit 1994 computerunterstützt an verschiedenen Körperteilen operiert.
Link: http://www.rp-online.de/news/wissenschaft/2001-0627/roboter_…

Wie man lesen kann, läßt sich der Neuromate über das ursprünglich vorgesehene Einsatzgebiet (Operationen im Hirnbereich) hinaus einsetzen. Das zweite Produkt, der ROBODOC(R), wurde vor allem nach Japan und nach Deutschland verkauft. (siehe News: http://www.bigcharts.com/news/symbolnews.asp?symb=RDOCE&sid=… ).

Gegenwärtig läuft das FDA-Zulassungsverfahren in den USA. Bei der Behandlung der von der FDA geforderten 180 Patienten ist es scheinbar zu Verzögerungen gekommen, da der angenommene Zeitplan (5 Monate) nicht gehalten werden konnte.

Integrated Surgical Systems Announces the Beginning of US Clinical Trials
MONDAY, DECEMBER 11, 2000 9:00 AM - PRNewswire
DAVIS, Calif., Dec 11, 2000 /PRNewswire via COMTEX/ -- Integrated Surgical Systems, Inc. (ISS) (Nasdaq: RDOC; EASDAQ), a pioneer in medical robotics and the world leader in image-directed, semi-autonomous robotic products for surgical applications, announced today that it will initiate the formal clinical trials for the Digimatch (Pinless) ROBODOC(R) Surgical Assistant System for the total hip arthroplasty.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000329/SFW037 )
William Bargar, MD, will perform the first surgery, which is planned for the third week in December, at the Sutter General Hospital in Sacramento. The other two sites are scheduled to start the clinical trials in January. The clinical trial, requiring a total of 180 patients, is expected to take five (5) months to complete. All the sites will use the VerSys(TM) line of cementless hip prostheses made by Zimmer, Inc., a subsidiary of Bristol-Myers Squibb (NYSE:BMY).
Once completed, the data from the studies will be submitted to the Food and Drug Administration for clearance under the recently agreed upon 510(k) "de Novo" classification.
THE PRODUCTS:
ROBODOC is the robotic surgery system of ISS that is used for total joint arthoplasties. ROBODOC consists of a robotic arm assembly and a PC-based 3-D planning station called ORTHODOC(R). ISS has installed 37 ROBODOC systems worldwide.
The ISS neurosurgery product, NeuroMate(TM), is the first robotic technology based system for use in stereotactic brain surgery. NeuroMate consists of a robotic arm assembly and a PC-based planning system. NeuroMate also interfaces with other popular planning stations offered by third-party vendors. ISS has installed 16 NeuroMate systems in the U.S., Europe, and Japan.
THE COMPANY:
Integrated Surgical Systems, Inc. develops, manufactures, markets and services computer-controlled, image-directed robotic products for surgical applications.
ISS produces the ROBODOC Surgical Assistant System (ROBODOC), which is designed for orthopedic applications. The ROBODOC System has been used to perform successful total hip replacement surgeries on more than 7,300 patients worldwide.
ROBODOC is currently being marketed in Europe and the Middle East. NeuroMate(TM), an ISS neurosurgery product, is the first robotic technology for use in stereotactic brain surgery and it has supported to date over 3,000 neurosurgical procedures.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including the timely development and market acceptance of new products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC).
NOTE: ROBODOC(R) is a registered trademark of Integrated Surgical Systems, Inc. NeuroMate(TM) is a trademark of Integrated Surgical Systems, S.A.
For more information on Integrated Surgical Systems via fax at no cost, please call 800-PRO-INFO (732-544-2850 outside the U.S.), ticker symbol RDOC.
SOURCE Integrated Surgical Systems, Inc.
CONTACT: Ramesh C. Trivedi, Ph.D., President and CEO, or Louis Kirchner, Chief Financial Officer, 530-792-2600, both of Integrated Surgical Systems
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000329/SFW037
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 201-369-3467
URL: http://www.robodoc.com
http://www.prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
Link: http://www.bigcharts.com/news/articles.asp?newsid=742073732&…

Kurse

Kommen wir zu der Aktie "RDOC". Integrated Surgical Systems wird seit Ende Mai an der OTC gehandelt, nachdem der Titel die 1$ rule der Nasdaq nicht mehr erfüllte.
Es kann mittlerweile festgestellt werden, daß RDOC börsentäglich gehandelt wird. Zum Teil kommt es sogar zu außergewöhnlichen Umsätzen wie z.B. am 27.6.2001.
Aktuelle Kurse findet ihr hier:
http://quotes.barchart.com/quote.asp?sym=rdoc&code=BSTK

Der Wechsel an die OTC wirkte sich auch auf das Listing an der EASDAQ und an deutschen Börsen aus. Nach dem Delisting an der EASDAQ wurden am 28.05.2001 die Notierungen der WPKN 908279 eingestellt. Die letzte Kursfeststellung erfolgte an diesem Tag in Frankfurt. In der Konsequenz kann die Aktie nun nur noch an der OTC ge- oder verkauft werden.
Die EASDAQ spielt hierbei m.E. eine unrühmliche Rolle hinsichtlich ihrer Vorgehensweise. Zuerst wird die Notierung am 14.02.2001 gelöscht, wobei noch nicht einmal das betroffene Unternehmen über diesen Schritt informiert wurde. Erst nachdem ISS intervenierte, wurde ein Schreiben aufgesetzt, demzufolge ISS innerhalb von 30 Tagen das Recht einer Anhörung zugestanden wurde. Am 02.03.2001 schließlich verzichtete Integrated Surgical Systems auf sein Beschwerderecht und stimmte dem EASDAQ-Delisting zu.
Es lohnt sich in jedem Fall, die zu diesem Vorgang gehörenden nachfolgenden Nachrichten zu lesen. Wie man aus der Info vom 02.03. erkennen kann, wurden von Seiten des Unternehmens Benachrichtigungen an die US-Aktionäre versandt. Dies entspricht (leider) einer typischen amerikanischen Verhaltensweise, bei der ausländische Aktionäre nicht oder nur selten vom jeweiligen Unternehmen Informationen erhalten.

Easdaq to discipline Integrated Surgical
WEDNESDAY, FEBRUARY 14, 2001 12:04 PM - Reuters
(Adds CEO comments in graphs 4,5)
BRUSSELS, Feb 14 (Reuters) - Easdaq, the pan-European stock exchange, said on Wednesday it began disciplinary action against U.S. medical robotics products maker Integrated Surgical Systems (NASDAQ SC:RDOC)(NASDAQ SC:RDOC) for alleged market violations.
Easdaq also said it halted trade in the stock, which was at a mid-price of 0.315 euros (29 cents). The stock closed on Tuesday at 25 cents on the Nasdaq.
The exchange said it began the action after Integrated Surgical violated several of its obligations as an issuer on the Brussels-based market.
Chief Executive Officer R.C. Trivedi of Davis, Ca.-based Integrated Surgical told Reuters the company has "not received any letter yet, so we don`t know what violations they`re saying we made. We don`t have the details."
Trivedi said his company was best known for its robotic system for orthopedic surgery, Robodoc, adding the company also has a robotic system used for performing neurosurgery.
An Easdaq spokeswoman could not immediately identify the violations, but said they fell under a chapter of the market`s rule book that lists such violations as failure to disclose financial information and failure to meet corporate governance requirements.
Easdaq said it was sending an formal letter, known as a notice of claim, to the U.S. company later on Wednesday.
"Integrated Surgical will have the right, if it so wishes, to submit a written statement to the Notice of Claim within 30 days of its receipt and to request a hearing," it said in a statement.
Integrated Surgical listed and began trading on Easdaq in November 1997.
The company is appealing a Nasdaq decision to delist its shares because they were trading below the $1.00 minimum.
(Additional reporting by Brian Kelleher in New York) Rtr 12:04 02-14-01
Copyright 2001, Reuters News Service
Link: http://www.bigcharts.com/news/articles.asp?newsid=770526395&…

Integrated Surgical Systems Announces the Listing of Its Stock Moved To the Bulletin Board
WEDNESDAY, FEBRUARY 14, 2001 10:21 PM - PRNewswire
DAVIS, Calif., Feb 14, 2001 /PRNewswire via COMTEX/ -- Integrated Surgical Systems, Inc. (Nasdaq: RDOC; Easdaq) (ISS), announced that it received a letter today, via facsimile, from the Nasdaq Listing Qualification Office that it has decided to delist the Company`s securities from the Nasdaq stock market effective February 14, 2001.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000329/SFW037 )
The Company also received a letter, via facsimile, today from Easdaq that it has decided to launch disciplinary proceedings against the Company for violating its obligations as an Easdaq issuer. Pending the outcome of the proceedings trading of the Company`s shares will be halted on the Easdaq.
As a result, the Company`s securities will now be listed on the Bulletin Board.
"We are obviously very disappointed with the decision made by Nasdaq in spite of our best efforts to persuade them otherwise. The Easdaq letter is being reviewed and we will respond promptly and appropriately. We are totally surprised by the letter and are unaware of not having met the obligations," commented Dr. Ramesh Trivedi, President and CEO of Integrated Surgical Systems.
THE PRODUCTS:
ROBODOC is the robotic surgery system of ISS that is used for total joint arthoplasties. ROBODOC consists of a robotic arm assembly and a PC-based 3-D planning station called ORTHODOC(R). ISS has installed 37 ROBODOC systems worldwide.
The ISS neurosurgery product, NeuroMate(TM), is the first robotic technology based system for use in stereotactic brain surgery. NeuroMate consists of a robotic arm assembly and a PC-based planning system. NeuroMate also interfaces with other popular planning stations offered by third-party vendors. ISS has installed 16 NeuroMate systems in the U.S., Europe, and Japan.
THE COMPANY:
Integrated Surgical Systems, Inc. develops, manufactures, markets and services computer-controlled, image-directed robotic products for surgical applications.
ISS produces the ROBODOC Surgical Assistant System (ROBODOC), which is designed for orthopedic applications. The ROBODOC System has been used to perform successful total hip replacement surgeries on more than 7,300 patients worldwide. ROBODOC is currently being marketed in Europe and the Middle East.
NeuroMate(TM), an ISS neurosurgery product, is the first robotic technology for use in stereotactic brain surgery and it has supported to date over 3,000 neurosurgical procedures.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including the timely development and market acceptance of new products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC). Note: ROBODOC(R) is a registered trademark of Integrated Surgical Systems, Inc. NeuroMate(TM) is a trademark of Integrated Surgical Systems, S.A.
For more information on Integrated Surgical Systems via fax at no cost, please call 800-PRO-INFO (732-544-2850 outside the U.S.), ticker symbol RDOC.
SOURCE Integrated Surgical Systems, Inc.
CONTACT: Ramesh C. Trivedi, Ph.D. - President and CEO of Integrated
Surgical Systems, 530-792-2600
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000329/SFW037
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 201-369-3467
URL: http://www.robodoc.com
http://www.prnewswire.com
(C) 2001 PR Newswire. All rights reserved.
Link: http://www.bigcharts.com/news/articles.asp?newsid=770672197&…

Integrated Surgical Systems Announces that EASDAQ has granted its request to delist ist securities
FRIDAY, MARCH 02, 2001 12:01 PM - PRNewswire
DAVIS, Calif., Mar 2, 2001 /PRNewswire via COMTEX/ -- Integrated Surgical Systems, Inc. (ISS) (Nasdaq: RDOC.OB), a pioneer in medical robotics and the world leader in image-directed, semi-autonomous robotic products for surgical applications, announced today that EASDAQ has granted its request to delist its securities. The delisting followed the delisting of the Company`s securities from The NASDAQ Stock Market.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000329/SFW037 )
The Company`s common stock and warrants are now traded on the NASD`s OTC Bulletin Board under the trading symbols RDOC.OB and RDOCW.OB, respectively. The Company files reports, proxy statements and other information with the United States Securities and Exchange Commission (the "SEC"). The Company`s filings are available from the SEC`s website at www.sec.gov.
Holders of the Company`s common stock are entitled to vote on all matters submitted to shareholders for their approval. Proxy statements for annual and special meetings of shareholders are distributed to shareholders.
THE PRODUCTS:
ROBODOC is the robotic surgery system of ISS that is used for total joint arthoplasties. ROBODOC consists of a robotic arm assembly and a PC-based 3-D planning station called ORTHODOC(R). ISS has installed 37 ROBODOC systems worldwide. The ISS neurosurgery product, NeuroMate(TM), is the first robotic technology based system for use in stereotactic brain surgery. NeuroMate consists of a robotic arm assembly and a PC-based planning system. NeuroMate also interfaces with other popular planning stations offered by third-party vendors. ISS has installed 16 NeuroMate systems in the U.S., Europe, and Japan.
THE COMPANY:
Integrated Surgical Systems, Inc. develops, manufactures, markets and services computer-controlled, image-directed robotic products for surgical applications.
ISS produces the ROBODOC Surgical Assistant System (ROBODOC), which is designed for orthopedic applications. The ROBODOC System has been used to perform successful total hip replacement surgeries on more than 8,000 patients worldwide. ROBODOC is currently being marketed in Europe and the Middle East.
NeuroMate(TM), an ISS neurosurgery product, is the first robotic technology for use in stereotactic brain surgery and it has supported to date over 3,000 neurosurgical procedures.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including the timely development and market acceptance of new products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC).
Note: ROBODOC(R) is a registered trademark of Integrated Surgical Systems, Inc. NeuroMate(TM) is a trademark of Integrated Surgical Systems, S.A.
SOURCE Integrated Surgical Systems, Inc.
CONTACT: Ramesh C. Trivedi, Ph.D., President and CEO of Integrated
Surgical Systems, 530-792-2600
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000329/SFW037
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 201-369-3467
URL: http://www.robodoc.com
http://www.prnewswire.com
(C) 2001 PR Newswire. All rights reserved.
Link: http://www.bigcharts.com/news/articles.asp?newsid=775778321&…

Mein privates Fazit:
Integrated Surgical Systems besitzt derzeit zwei interessante Produkte mit großen und durchaus auch zukunftsträchtigen Einsatzbereichen.
Eine Zulassung durch die FDA sollte für den amerikanischen Titel den Durchbruch bedeuten (dies entspricht einem typischen amerikanischen Marktverhalten: Unternehmen, welche nicht im eigenen Land Produkte verkaufen, werden i.d.R. ignoriert).
Kurzfristig muß das Liquiditäts- und Schuldenproblem gelöst werden. (aktuelles EPS -0.91)

Über sachliche Kommentare würde ich mich freuen.
MfG NoFear

[NoFear]

"Das Parkettgespräch" mit Laura Rossi (BB Medtech)
Quelle: FAZ vom 20.07.2001 Seite 25

Im Schatten der Biotechnik

"Das Thema ist nun einmal nicht so emotional besetzt." Für Laura Rossi, Portfolio-Managerin bei der auf Medizintechnik
spezialisierten Schweizer Beteiligungsgesellschaft BB Medtech, ist dies die wichtigste Erklärung dafür, warum
Medizintechnik-Unternehmen an der Börse im Vergleich zu Biotechnik-Werten eher ein Schattendasein führen. Was in der
Medizintechnik fehlt, sind die großen Heilversprechungen. "Die Ankündigung eines neuen Medikaments gegen Brustkrebs
findet nun einmal mehr Aufmerksamkeit als die Nachricht von einem neuen Zahnimplantat", sagt Rossi. Darüber hinaus gebe
es in der Medizintechnik kaum sogenannte Blockbuster-Geschichten wie in der Biotechnik, also einzelne
Produkte, die Umsätze in Milliardenhöhe versprechen.

Zur Medizintechnik gehören die unterschiedlichsten Produkte. Allgemein versteht man darunter alle Arten von Instrumenten
und Apparaten zur Erkennung, Verhütung und Behandlung von Krankheiten. Der Kernspintomograph gehört dazu ebenso wie
das Hörgerät oder der Herzschrittmacher. Das Marktvolumen ist riesig: Nach Schätzungen von Rossi wird mit
Medizintechnik auf der Welt ein Umsatz von 150 Milliarden Dollar erzielt, das jährliche Wachstum liegt - nicht zuletzt
aufgrund einer immer weiter steigenden Lebenserwartung in den Industrieländern - zwischen 8 und 10 Prozent. Einzelne
Gebiete der Medizintechnik versprechen nach den Worten von Rossi ebensoviel Wachstum, wie man es aus vielen Segmenten
der Biotechnik kennt. So habe der Markt für Wirbelsäulenimplantate - Metall- oder Knochenteile, die zur
Stützung der Wirbelsäule eingesetzt werden - mittlerweile ein Volumen von 2 Milliarden Dollar und wachse mit 25 bis 30
Prozent im Jahr. Bei Dentalimplantaten (Marktvolumen: 600 Millionen Dollar) sei im laufenden Jahr ein Wachstum zwischen
16 und 18 Prozent zu erwarten. "200 Millionen Menschen in Industrieländern fehlt mindestens ein Zahn", verdeutlicht sie
das Potential dieses Marktes.

Am Neuen Markt gibt es einen eigenen Sub-Index "Medtech & Health Care", der allerdings von den insgesamt zehn
Untergruppen die geringste Marktkapitalisierung aufweist. Der Index besteht aus 13 Unternehmen. Darunter befinden sich
neben Medizintechnik-Spezialisten auch der angeschlagene Pflegeheimbetreiber Refugium und das kleine
Klinikunternehmen Euromed. Auch BB Medtech ist dort vertreten. Der Medtech-Index hat wie der gesamte Neue Markt
in den vergangenen Monaten deutlich an Wert verloren. Vor einem Jahr notierte er bei rund 130 Punkten, am Donnerstag
stand er bei 64 Punkten.

Der Absturz fiel jedoch weniger dramatisch aus als im Biotechnik-Index, der nur noch ein Drittel seines Wertes von
vor einem Jahr hat. Freilich waren die Kursgewinne in der Biotechnik vorher weit höher als in der Medizintechnik.

Allgemein findet Rossi die am Neuen Markt notierten Werte wenig beeindruckend, im Portfolio von BB Medtech findet sich
keines dieser Unternehmen. "Die interessanten Medizintechnik-Unternehmen kommen nicht aus Deutschland",
sagt sie. Die deutschen Unternehmen seien vor allem Nischenspieler, wenn auch zum Teil in wachstumsstarken
Segmenten. Außerdem mangele es ihnen an internationaler Präsenz, insbesondere in den Vereinigten Staaten, wo die
höchsten Margen zu erzielen sind. Am Neuen Markt fehle ein wirklich großes Vorzeige-Unternehmen, wie es etwa Qiagen in
der Biotechnik ist.

Die interessantesten Werte sind nach Meinung von Rossi in den Vereinigten Staaten zu finden, darüber hinaus gebe es in Europa
vor allem in der Schweiz und in Nordeuropa vielversprechende Unternehmen. Zu den größten Positionen im Portfolio von BB
Medtech gehört die Aktie von Nobel Biocare, ein auf Zahnimplantate spezialisiertes Unternehmen aus Schweden,
Synthes-Stratec, ein Schweizer Orthopädie-Unternehmen, sowie die amerikanische Gesellschaft Medtronic, die vor allem
Produkte zur Behandlung von Herzrhythmusstörungen herstellt. Darüber hinaus nennt Rossi als weitere interessante
Unternehmen Guidant (Gefäßprothesen) und St. Jude Medical (Herzschrittmacher) aus den Vereinigten Staaten und
Disetronic (Infusionspumpen) aus der Schweiz.

Den Anlegern rät Rossi, auf die großen Marktführer in ihren jeweiligen Segmenten zu setzen, wenn man sich langfristig in
der Medizintechnik engagieren möchte. Die kleineren Werte und damit alle Werte am Neuen Markt eignen sich ihrer
Meinung nach eher für kurzfristige Investitionen. Kurspotential könnte sich bei diesen Aktien möglicherweise durch
Übernahmephantasien ergeben. Rossi kann sich vorstellen, daß einige kleinere Unternehmen aus dem Neuen Markt unter das
Dach einer großen Gesellschaft schlüpfen. Ein erstes Beispiel dafür gab es Anfang dieser Woche. Das auf Ultraschallgeräte
spezialisierte österreichische Unternehmen Kretztechnik hat ein Übernahmeangebot von der
Medizintechnik-Tochtergesellschaft des amerikanischen Mischkonzerns General Electric erhalten.

Allgemein sieht Rossi das größte Wachstumspotential in den Bereichen Orthopädie und Kardiologie. Weniger attraktiv seien
dagegen die Ausrüster von Krankenhäusern, also Hersteller von Patientenüberwachungsgeräten oder Hilfsmitteln wie Skalpelle
und Mullbinden. Diese Bereiche seien allein durch Ausgabenbeschränkungen der öffentlichen Hand in ihrem
Wachstum limitiert. "Die Perspektiven liegen dort, wo es um den einzelnen Patienten geht", sagt Rossi.

ROLAND LINDNER
Laura Rossi BB Medtech
Frankfurter Allgemeine Zeitung, 20.07.2001, Nr. 166 / Seite 25
http://www.faz.de/IN/INtemplates/faznet/default.asp?tpl=faz/…

Relevanz des Artikels für Integrated Surgical Systems (RDOC):

- Das größte Wachstumspotential sieht die Portfolio-Managerin in den Bereichen Orthopädie und Kardiologie.
RDOC ist mit zwei etablierten Produkten auf dem Markt:
ROBODOC(R) -> Bereich Orthopädie (!)
NeuroMate -> Bereich Neurochirurgie, ab Herbst Einsatz bei Wirbelsäulenoperationen (siehe Nachricht vom 27.06.2001 im oberen Threadteil)

- Die interessantesten Werte im Medizintechnikbereich sind in den Vereinigten Staaten zu finden.
Deutsche Unternehmen sind mangels Qualität und geringer Größe für die Portfolio-Managerin uninteressant.



Think about it.
Any comments ?

MfG NoFear" target="_blank" rel="nofollow ugc noopener">http://www.faz.de/IN/INtemplates/faznet/default.asp?tpl=faz/…

Relevanz des Artikels für Integrated Surgical Systems (RDOC):

- Das größte Wachstumspotential sieht die Portfolio-Managerin in den Bereichen Orthopädie und Kardiologie.
RDOC ist mit zwei etablierten Produkten auf dem Markt:
ROBODOC(R) -> Bereich Orthopädie (!)
NeuroMate -> Bereich Neurochirurgie, ab Herbst Einsatz bei Wirbelsäulenoperationen (siehe Nachricht vom 27.06.2001 im oberen Threadteil)

- Die interessantesten Werte im Medizintechnikbereich sind in den Vereinigten Staaten zu finden.
Deutsche Unternehmen sind mangels Qualität und geringer Größe für die Portfolio-Managerin uninteressant.



Think about it.
Any comments ?

MfG NoFear

[murmeltier]

Vielen Dank für die aufschlußreichen Neuigkeiten und Kommentare.

Ich kann zwar selbst nichts zu diesem Wert beisteuern, verfolge aber gelegentlich neue Diskussionen über Integrated Surg. Systems in diesem Board.

Meine RDOCs halte ich jedenfalls solange, bis ich wieder im Plus mit denen bin, und das sind noch mehrere 100%.

Murmeltier

[NoFear]

Heute im Angebot: Quartalszahlen

10QSB: INTEGRATED SURGICAL SYSTEMS INC

FRIDAY, JULY 27, 2001 8:16 AM
- Edgar Online
(EDGAR Online via COMTEX) -- Item 2. Management`s Discussion and Analysis

Results of Operations

Net sales of $1.6 million for the three months ended March 31, 2001, were 12% lower than the level achieved in the
same period of 2000. While revenue for the first quarter of 2001 included no recognized systems sales, the same
period in the previous year included systems sales of $1.1 million. Systems services revenue, at approximately 1.3
million for the first quarter of 2001, was higher than the $.7 recorded in the first quarter of 2000 because more systems
were in the field, creating more servicing and consumables opportunity. We also earned approximately $354,000 in
revenue from implant library development in the first three months of 2001, but none in the comparable period of 2000.

The first quarter 2000 gross margin of 52% improved to 71% in the first quarter of 2001 due to the higher margin
services in 2001 versus the systems sales of 2000.

Selling, general and administrative ("SG&A") expense at $1.2 million for the three month ended March 31, 2001 is
approximately $295,000 higher than for the same period of 2000. During the first quarter of 2000, we were operating
under an exclusive European distribution agreement, and most sales and marketing expenses were transferred to the
distributor. In the first quarter of 1999, when, as now, these costs were incurred in full, SG&A expenses were $1.4
million. The first quarter 2001 51% reduction in research and development expenseversus the first quarter of 2000 is
the result of headcount elimination and other cost-savings measures undertaken in 2000 in response to lowered sales
projections.

Other expenses increased approximately $26,000 during the three months ended March 31, 2001 over the same
period in 2000, primarily due to an increase in our currency exchange loss (from $143,000 in 2000 to $167,000 in
2001) as the dollar continued to strengthen against European currencies.

Liquidity

The report of our independent auditors on our 2000 consolidated financial statements included an explanatory
paragraph indicating that there is substantial doubt with respect to the Company`s ability to continue as a going
concern. Since inception, our expenses have exceeded our revenue, and operations have been funded primarily
through the sale of equity securities. As discussed below under "Capital Resources," it is unlikely that the equity
markets will continue to support fund-raising at historic levels. We believe, however, that we have begun to generate
sales at a level sufficient to ensure our survival through the remainder of 2001. Although we believe that our plan will be
realized, there is no assurance that these events will occur. The consolidated financial statements do not include any
adjustments to reflect the uncertainties related to the recoverability and classification of assets or the amounts and
classification of liabilities that may result from our inability to continue as a going concern.

Our cash balance at March 31, 2001 was $145,000 below the balance at December 31, 2000 and $896,000 below the
cash balance at the end of the first quarter of 2000. During the first quarter of 2000, we raised $2 million through the
sale of convertible preferred stock, while during the first quarter of 2001, we raised $550,000 through our equity
financing line. The increased revenue of the first quarter of 2001 versus 2000 closed some of this funding gap, but on
March 31, 2001, our current liabilities exceeded our current assets and it has been difficult for us to meet our
obligations as they become due.

Inventory decreased $655,000 from December 31, 2000 to March 31, 2001, providing our greatest source of operating
cash for the three months then ended. Unearned revenue represents 52% of our liabilities at March 31, 2001 and
includes payments for systems sales on which revenue is not yet recognized, as well as advance payment for service
contracts which revenue is recognized ratably over the period of the contract. Our largest use of cash, a $371,000
increase in accounts receivable, represents unpaid balances due on systems shipped near the end of the quarter, for
which revenue has not yet been recognized.

Capital Resources

In the first quarter of 2001, our common stock and warrants were delisted from the NASDAQ because the stock did
not maintain the exchange`s minimum bid price of $1.00 per share. On May 24th, the OTC Bulletin Board ceased
providing quotes for ourcommon stock and warrants because we had not filed our Form 10-KSB for the year ended
December 31, 2000 and this Form 10-QSB for the quarter ended March 31, 2001 with the Securities and Exchange
Commission ("SEC"). Quotes for our common stock and warrants are now available only through the pink sheets.

Our annual report on Form 10-KSB was filed on June 27, 2001 and with the filing of this Form 10-QSB, we believe that
we are in compliance with all of our SEC filing obligations. There is no assurance, however, that the OTC Bulletin
Board will resume its quotation of our common stock. Without the visibility and the implied increase in trading volume
afforded by Bulletin Board coverage, it is likely that our equity fundraising activities will be limited.

We have received net proceeds of $742,000 through our equity line of credit from inception through June 30, 2001, and
through that date, have $11.3 million in additional credit on which to draw. However, the price of our common stock,
$0.12at June 30, 2001, means that the use of the equity line of credit causes significant dilution to our common
shareholders.

(c) 1995-2001 Cybernet Data Systems, Inc. All Rights Reserved
Received by Edgar Online Jul 27, 2001

Persönlicher Kommentar: ISS lebt (weiter)!
Wie das Unternehmen unter dem Punkt "Liquidity" erwähnt, war der unabhängige Bilanzprüfer für den Jahresabschluß 2000 in
keinster Weise von Fortbestehen der Firma überzeugt (nachzulesen im Newsteil von RDOC).
Die Unternehmensführung glaubt, daß sie die Existenz von ISS über das Jahr 2001 hinaus wird sichern können.
Weiter darf sich in den Staaten keine Firma aus dem Fenster lehnen (da sind die Bestimmungen der SEC vor).

Interessant finde ich die Tatsache, daß die Einkünfte im Servicebereich fast verdoppelt wurden (von 0.7 auf 1.3 Millinen $)
und so einen Großteil der Einkünfte aus dem Vergleichquartal (aus Systemverkäufen, welche in diesem Quartal vollständig
ausblieben) auffangen konnte. Man darf auf die weitere Entwicklung gespannt sein.

MfG NoFear

[Chalet]

Hallo all,
hätte nie gedacht, dass es noch einige Leute gibt, die in RDOC investiert sind. Die Aktien lümmelt so in meinem Depot herum und ist schon so billig, dass ein Verkauf garnicht mehr lohnt. Ich bin damals, d.h. 05/00 in einem Artikel von Report 21 auf diese Aktie aufmerksam geworden. Naja, wie jeder weiß, war das nicht unbedingt deeer Augenblick, um Aktien zu kaufen. Eigentlich gibt es auch Stopploss, richtig..... wie das nun mal so ist mit den guten Vorsätzen.
Hoffen wir auf bessere Zeiten...
Gruß an alle
Chalet.

[dontrader]

Hallo zusammen,

FDA is coming. Ende September bis Ende Oktober werden wir alle für unser langes warten belohnt werden.

[NoFear]

Wieder einmal: Neues von RDOC
Heute: Quartalszahlen für das 2. Quartal 2001


TUESDAY, AUGUST 14, 2001 8:51 AM - Edgar Online

(EDGAR Online via COMTEX) -- Item 2. Management`s Discussion and Analysis

Results of Operations

Net sales of $2.4 million for the three months ended June 30, 2001 were more than double the sales of the second
quarter of 2000, bringing year-to- date 2001 sales to 135% of their 2000 level. Revenue for the second quarter
of 2001 included three systems sales (two ROBODOC(R)s and one NeuroMate(R)) while the 2000 period contained only
one ROBODOC(R) sale.

Selling, general and administrative ("SG&A") expense at $981,000 for the three months ended June 30, 2001 is
$92,000 lower than for the same period of 2000the result of continued cost containment. The comparative SG&A
increase of $203,000 for the first half of 2001 over the first half of 2000 was the result of the transfer of
most sales and marketing expense to a European distributor during the first quarter of 2000. In the first half
of 1999, the last comparable period in which these costs were incurred in full, SG&A expenses were $3.1 million.
Research and development expenses for 2001 show the effect of cost-savings measures undertaken in 2000 in
response to lowered sales projections.

Other income for the three month period ended June 30, 2000 included approximately $740,000 of licensing fees
paid to the Company under an exclusive distribution agreement which was terminated in May 2000. No corresponding
income was received in 2001. The other major component of other expense, foreign currency exchange loss,
increased $169,000 during the first six months of 2001 over the comparable period of 2000 as the dollar
strengthened against European currencies.

Liquidity

The report of our independent auditors on our 2000 consolidated financial statements included an explanatory
paragraph indicating that there is substantial doubt with respect to the Company`s ability to continue as a
going concern. Since inception, our expenses have exceeded our revenue, and operations have been funded primarily
through the sale of equity securities. As discussed below under "Capital Resources," it is unlikely that the
equity markets will continue to support fund-raising at historic levels. We believe, however, that we have begun
to generate sales at a level sufficient to ensure our survival through the remainder of 2001. Although we believe
that our plan will be realized, there is no assurance that these events will occur. The consolidated financial
statements do not include any adjustments to reflect the uncertainties related to the recoverability and
classification of assets or the amounts and classification of liabilities that may result from our inability to
continue as a going concern.

Our cash balance at June 30, 2001 was half of the cash balance at the end of the second quarter of 2000, but has
increased $261,000 from the balance at December 31, 2000. During the first half of 2000, we raised $2.3 million,
net of redemptions, through the sale of convertible preferred stock, while during the first half of 2001, we
raised $667,000 through our equity financing line. The increased revenue of the first half of 2001 versus 2000
closed some of this funding gap, but on June 30, 2001, our current liabilities exceeded our current assets,
accounts payable contributed $378,000 to cash flow over the six month period, and it has been difficult for us
to meet our obligations as they become due.

Inventory provided $876,000 to cash flow during the six months ended June 30, 2001, as systems were shipped from
supplies already on hand. Unearned income, at $2.8 million, represented 51% of the company`s liabilities at
June 30, 2001, an increase in cash flow of $432,000 over December 31, 2000. Unearned income includes payments for
systems sales on which revenue is not yet recognized, as well as advance payment for service contracts which
revenue is recognized ratably over the period of the contract and deposits on product development contracts. Our
$196,000 cash flow impact from accounts receivable, our largest use of cash since December 31, 2000, represents
unpaid balances due on products shipped near the end of the second quarter, for which revenue has not yet been
recognized.

Capital Resources

In the first quarter of 2001, our common stock and warrants were delisted from the NASDAQ because the stock did
not maintain the exchange`s minimum bid price of $1.00 per share. On May 24th, the OTC Bulletin Board ceased
providing quotes for our common stock and warrants because we had not filed our Form 10-KSB for the year ended
December 31, 2000 and our Form 10-QSB for the quarter ended March 31, 2001 with the Securities and Exchange
Commission ("SEC"). Quotes for our common stock and warrants are now available only through the pink sheets.

Our annual report on Form 10-KSB was filed on June 27, 2001 and our Form 10-QSB for the quarter ended March 31,
2001 was filed on July 26, 2001 and we believe that we are now in compliance with all of our SEC filing
obligations. There is no assurance, however, that the OTC Bulletin Board will resume its quotation of our
common stock. Without the relative visibility which would accompany Bulletin Board coverage, it is likely that
our equity market activities will be limited.

We have received net proceeds of $742,000 through our Private Equity Line of Credit Agreement from inception
through August 1, 2001, and through that date, have $11.3 million in additional credit on which to draw. However,
the price of our common stock, $0.12 at June 30, 2001, means that the use of the equity line of credit causes
significant dilution to our common shareholders.

(c) 1995-2001 Cybernet Data Systems, Inc. All Rights Reserved

Received by Edgar Online Aug 14, 2001

Link: http://bigcharts.marketwatch.com/news/articles.asp?newsid=78…


Wenn man die Pflichtberichtsphrasen wegläßt, ergeben sich die folgenden (m.E. wichtigsten)
hard facts auf Monatsvergleichsbasis :

Net sales
Q1 2001 no recognized systems sales (systems sales of $1.1 million in Q1 2000)
Q2 2001 2 ROBODOC and 1 NeuroMate (1 Robodoc in Q2 2000)

Net revenues
Q1 2001 1.6 million $ (- 12 % compared to Q1 2000)
Q2 2001 2.4 million $ (+135 % compared to Q2 2000)



"SG & A" expenses
Q1 2001 1.200 000 $ (+295 000 $ compared to Q1 2000)
Q2 2001 981 000 $ (- 92 000 $ compared to Q2 2000)


Weitere nachlesbare Vergleichsdaten beziehen sich auf Vergleiche der Halbjahresergebnisse.

Interessant ist nachfolgender Satz im Absatz "Liquidity" :
"Our $196,000 cash flow impact from accounts receivable, our largest use of cash since
December 31, 2000, represents unpaid balances due on products shipped near the end of the
second quarter, for which revenue has not yet been recognized."
Ich interpretiere den Satz folgendermaßen: Ein neues System (ROBODOC oder NeuroMate) wurde
noch zum Ende des ersten Halbjahres 2001 per Schiff ausgeliefert. Die Bezahlung von
Intergated Surgical Systems erfolgt wahrscheinlich erst nach der Inbetriebnahme des Systems
(Aufstellort wahrscheinlich in Deutschland oder in Japan).
Die Einkünfte für diese (bereits ausgelieferte) Apparatur erscheinen somit erst im
3.Quartal 2001.

Any comments ?

Best invest.
NoFear

[NoFear]

Neuigkeiten vom 17.10.2001



Integrated Surgical Systems Announces Successful Surgery at Its Second U.S. Clinical Trial Site

WEDNESDAY, OCTOBER 17, 2001 6:50 PM
- PRNewswire

DAVIS, Calif., Oct 17, 2001 /PRNewswire via COMTEX/ -- Integrated Surgical Systems, Inc. (OTC:RDOC), a pioneer in
medical robotics and the world leader in image-directed, semi-autonomous robotic products for surgical applications,
today announced the successful completion of the first ROBODOC(R) Surgical Assistant System hip replacement surgery
at it second clinical trial site, the University of Arkansas Medical Sciences.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000329/SFW037 )

The U.S. clinical trials, which require a total of 188 subjects at three sites, began in December 2000. Since that time, 35
successful procedures have been performed at Sutter General Hospital in Sacramento, California. While the company
hoped that clinical trials at the University of Arkansas would begin in early 2001, the Internal Review Board (IRB) approval
process took longer than anticipated. The addition of the third clinical trial site is also dependent upon IRB approval, but
the company hopes that all clinical trial surgeries can be completed by mid-2002.

At the conclusion of the clinical trials, the company will seek FDA clearance to market the ROBODOC(R) System in the
U.S. ROBODOC(R) has already been used to perform more than 9,000 joint replacement procedures in Europe and
Japan.

Integrated Surgical Systems designs, manufactures, sells and services image-directed, computer controlled robotic
products for use in orthopaedic and neurosurgical procedures. Our ROBODOC(R) Surgical Assistant System is the
world`s leading robotic system for hip and knee replacement surgery. NeuroMate(TM), our neurosurgery system, is the
first robotic technology based system for use in stereotactic brain surgery.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking
statements that involve risks and uncertainties, including the timely development and market acceptance of new products
and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed from time to
time in the company`s filings with the Securities and Exchange Commission (SEC).

NOTE: ROBODOC(R) is a registered trademark of Integrated Surgical Systems, Inc. NeuroMate(TM) is a trademark of
Integrated Surgical Systems, S.A. www.robodoc.com.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X24493841

SOURCE Integrated Surgical Systems, Inc.

CONTACT: Ramesh C. Trivedi, Ph.D., President and CEO, or Patricia Pilz,
CFO, [phone], both of Integrated Surgical Systems, Inc.
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000329/SFW037
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 1-888-776-6555 or [phone]

URL: http://www.robodoc.com
http://www.prnewswire.com

Copyright (C) 2001 PR Newswire. All rights reserved.
http://bigcharts.marketwatch.com/news/articles.asp?newsid=79…


Was will uns die Meldung sagen ? Nun, 2/3 des FDA-Approvals sind "im Sack".
Mit etwas Fortune erkennt die FDA im Rahmen des Zulassungsverfahrens vielleicht die
Patientenzahlen in Europa und in Japan ganz oder zumindest teilweise an ......
ISS will sich zumindest darum bemühen (siehe Text).
Der Abschluß des Verfahrens wird für Mitte 2002 erwartet.


Any comments ?

Best invest
NoFear

[NoFear]

Weekly News: ISS erschließt sich neue Märkte durch einen Vertrag mit DePuy International
(zur Johnson & Johnson Unternehmensgruppe gehörend)


Integrated Surgical Systems Signs Software Development Agreement With DePuy International
WEDNESDAY, OCTOBER 24, 2001 3:00 PM
- PRNewswire

Integrated Surgical Systems Signs Software Development Agreement With DePuy International

DAVIS, Calif., Oct 24, 2001 /PRNewswire via COMTEX/ -- Integrated Surgical Systems, Inc. (ISS) , a pioneer in
medical robotics and the world leader in image-directed, semi-autonomous robotic products for surgical applications,
announced today that it has signed a major agreement with DePuy International Ltd., a Johnson & Johnson
company, to develop ROBODOC(R) software for DePuy`s hip and knee prostheses.

"DePuy is a major player in the orthopedic market and so we are pleased to enter into this agreement with them. We
know that many orthopedic surgeons are happy to have a greater choice of prostheses to select from in order to
ensure an optimal implant for their patients. When introduced, the software will be made available on a worldwide
basis," commented Dr. Ramesh Trivedi, President & CEO of Integrated Surgical Systems.

(Photo: )

On October 17, ISS announced the successful completion of the first ROBODOC(R) Surgical Assistant System hip
replacement surgery at it second clinical trial site, the University of Arkansas Medical Sciences.

The U.S. clinical trials, which require a total of 188 subjects at three sites, began in December 2000. Since that
time, 35 successful procedures have been performed at Sutter General Hospital in Sacramento, California. While the
company hoped that clinical trials at the University of Arkansas would begin in early 2001, the Institutional Review
Board (IRB) approval process took longer than anticipated. The addition of the third clinical trial site is also
dependent upon IRB approval, but the company hopes that all clinical trial surgeries can be completed by mid-2002.

At the conclusion of the clinical trials, the company will seek FDA clearance to market the ROBODOC(R) System in
the US. ROBODOC(R) has already been used to perform more than 9,000 joint replacement procedures in Europe
and Japan.

Integrated Surgical Systems designs, manufactures, sells and services image-directed, computer-controlled robotic
products for use in orthopaedic and neurosurgical procedures. The ROBODOC(R) Surgical Assistant System is the
world`s leading robotic system for hip and knee replacement surgery. NeuroMate(TM), the company`s neurosurgery
system, is the first robotic technology based system for use in stereotactic brain surgery.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking
statements that involve risks and uncertainties, including the timely development and market acceptance of new
products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed
from time to time in the company`s filings with the Securities and Exchange Commission (SEC).

NOTE: ROBODOC(R) is a registered trademark of Integrated Surgical Systems, Inc.

SOURCE Integrated Surgical Systems, Inc.

Copyright (C) 2001 PR Newswire. All rights reserved.

http://bigcharts.marketwatch.com/news/articles.asp?guid={CF5…




Ob die Talsohle nunmehr durchschritten ist ??? Let`s wait and see.


Any comments ?


Best invest
NoFear

Any

[heraklit]

Hallo no fear,

danke für deine Arbeit!

Hoffentlich gibts die FDA Clearance bald,
darauf warte ich schon 2 Jahre!

panta rhei,

heraklit

[heraklit]

Hallo zusammen,

Neues Sec Filing, alle Warrants
werden 1 Jahr verlängert!

Meinungen?


panta rhei,

heraklit

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549




FORM 8-K



CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report: October 30, 2001



INTEGRATED SURGICAL SYSTEMS, INC.




Delaware
(State of Incorporation)

1-12471
(Commission File Number)

68-0232575
(IRS Employer Identification No.)


1850 Research Park Drive
Davis, CA 95616-4884
(Address of principal executive offices)

[phone]
(Registrant`s telephone number)



Item 5. Other Events

On October 25, 2001 the board of directors of Integrated Surgical Systems, Inc.
voted to extend for twelve months the expiration date of all of the company`s
currently outstanding warrants to purchase common stock. The various warrant
issues, the number of warrants outstanding, the number of shares of common
stock which the warrants may purchase, the exercise price and the extended
expiration date are listed below:



Warrant Number of Number of Exercise Extended
Warrants Shares Price Expiration Date

IBM 2,206,479 2,206,479 $0.0100 December 31, 2006
IPO public offering 1,567,000 6,112,552 1.5400 November 19, 2002
IPO underwriters (1) 339,250 1,323,344 1.5400 November 19, 2002
IPO underwriters (2) 152,500 663,384 1.9000 November 19, 2002
Rickel &
Associates, Inc. 25,000 105,510 1.7800 September 4, 2003
EASDAQ underwriters 150,000 654,680 1.9100 November 21, 2003
Series B Preferred 12,500 12,500 2.7500 March 25, 2003
Series C Preferred 9,375 9,375 2.1531 June 9, 2003
Series D Preferred 25,000 25,000 3.4125 June 29, 2003
Series E Preferred 37,500 37,500 4.3880 July 29, 2003
Series F Preferred 125,000 125,000 2.3750 February 7, 2004
Series G Preferred 63,000 63,000 1.8750 May 29, 2004
Series H Preferred (1) 300,000 300,000 0.9344 August 16, 2004
Series H Preferred (2) 250,000 250,000 1.0156 August 16, 2004
Series H Preferred (3) 100,000 100,000 0.5000 August 16, 2004
Equity Line 35,000 35,000 0.8590 September 14, 2004
ILTAG International
Licensing Holding
S.A.L. 4,000,000 4,000,000 1.0270 December 13, 2003
__________
16,023,324






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



Integrated Surgical Systems, Inc.


Dated: 30th October 2001
By: /s/ PATRICIA PILZ

Patricia Pilz

Chief Financial Officer

[heraklit]

Hallo zusammen,

noch einmal, da beim ersten Mal anscheinend nicht durchgegangen:

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549




FORM 8-K



CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report: October 30, 2001



INTEGRATED SURGICAL SYSTEMS, INC.




Delaware
(State of Incorporation)

1-12471
(Commission File Number)

68-0232575
(IRS Employer Identification No.)


1850 Research Park Drive
Davis, CA 95616-4884
(Address of principal executive offices)

[phone]
(Registrant`s telephone number)



Item 5. Other Events

On October 25, 2001 the board of directors of Integrated Surgical Systems, Inc.
voted to extend for twelve months the expiration date of all of the company`s
currently outstanding warrants to purchase common stock. The various warrant
issues, the number of warrants outstanding, the number of shares of common
stock which the warrants may purchase, the exercise price and the extended
expiration date are listed below:



Warrant Number of Number of Exercise Extended
Warrants Shares Price Expiration Date

IBM 2,206,479 2,206,479 $0.0100 December 31, 2006
IPO public offering 1,567,000 6,112,552 1.5400 November 19, 2002
IPO underwriters (1) 339,250 1,323,344 1.5400 November 19, 2002
IPO underwriters (2) 152,500 663,384 1.9000 November 19, 2002
Rickel &
Associates, Inc. 25,000 105,510 1.7800 September 4, 2003
EASDAQ underwriters 150,000 654,680 1.9100 November 21, 2003
Series B Preferred 12,500 12,500 2.7500 March 25, 2003
Series C Preferred 9,375 9,375 2.1531 June 9, 2003
Series D Preferred 25,000 25,000 3.4125 June 29, 2003
Series E Preferred 37,500 37,500 4.3880 July 29, 2003
Series F Preferred 125,000 125,000 2.3750 February 7, 2004
Series G Preferred 63,000 63,000 1.8750 May 29, 2004
Series H Preferred (1) 300,000 300,000 0.9344 August 16, 2004
Series H Preferred (2) 250,000 250,000 1.0156 August 16, 2004
Series H Preferred (3) 100,000 100,000 0.5000 August 16, 2004
Equity Line 35,000 35,000 0.8590 September 14, 2004
ILTAG International
Licensing Holding
S.A.L. 4,000,000 4,000,000 1.0270 December 13, 2003
__________
16,023,324






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



Integrated Surgical Systems, Inc.


Dated: 30th October 2001
By: /s/ PATRICIA PILZ

Patricia Pilz

Chief Financial Officer

panta rhei,

heraklit

[NoFear]

Meinungen ..... ?

Ich bin nicht allein !


Anbei der Link zur News: http://biz.yahoo.com/prnews/011030/sftu107_1.html


Wird vielleicht doch nichts mehr mit Wohnung tapezieren .... ...... langfristig gesehen
Other comments ?

Best invest
NoFear

[NoFear]

Es ist noch Suppe da ...

Integrated Surgical Systems Enters the French Market With the ROBODOC Surgical Assistant
System


WEDNESDAY, OCTOBER 31, 2001 7:31 PM
- PRNewswire

Integrated Surgical Systems Enters the French Market With the ROBODOC Surgical Assistant System

DAVIS, Calif., Oct 31, 2001 /PRNewswire via COMTEX/ -- Integrated Surgical Systems, Inc. (ISS) , a pioneer in
medical robotics and the world leader in image-directed, semi-autonomous robotic products for surgical applications,
announced today that it has sold and installed a ROBODOC(R) System at Hopital Intercommunal
d`Eaubonne-Montmorency in Eaubonne, France.

(Photo: )

"This is our first ROBODOC System in France, and we are excited to be represented in one of Europe`s largest
markets. Dr. Francois Aubart, Chief of the Orthopedic Department, is recognized as a leader in robotic surgery and
we are delighted that he decided to switch to the ROBODOC," commented Dr. Ramesh Trivedi, President & CEO of
ISS.

Integrated Surgical Systems designs, manufactures, sells and services image-directed, computer controlled robotic
products for use in orthopaedic and neurosurgical procedures. The ROBODOC Surgical Assistant System is the
world`s leading robotic system for hip and knee replacement surgery. NeuroMate(TM), the company`s neurosurgery
system, is the first robotic technology based system for use in stereotactic brain surgery.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking
statements that involve risks and uncertainties, including the timely development and market acceptance of new
products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed
from time to time in the company`s filings with the Securities and Exchange Commission (SEC).

NOTE: ROBODOC(R) is a registered trademark of Integrated Surgical Systems, Inc. NeuroMate(TM) is a trademark
of Integrated Surgical Systems, S.A. .

SOURCE Integrated Surgical Systems, Inc.

Copyright (C) 2001 PR Newswire. All rights reserved.


Quelle : http://bigcharts.marketwatch.com/news/articles.asp?guid={82F…

Interessant finde ich das Wort "sold". Frühere Meldungen enthielten diesen Passus nicht. Gemessen an dem Stückpreis für ein derartiges System
gab es somit diesmal keine Leasingregelung. Der Verkauf wird voll ergebniswirksam. Möglicherweise (??) handelt es sich um den "ROBODOC", welcher
beim letzten Quartalsergebnis (siehe weiter oben) gerade per Schiff nach Europa transportiert hatte und als "Lagervorrat" die Bilanz belastete.
Man kann gleichfalls feststellen, daß die PR und IR in letzter Zeit einiges zu tun hatte.
Es darf so weitergehen ....

Any comments ?

Best invest
NoFaer

[heraklit]

Hi NoFear,

seltsam, dass trotz der positiven News
der Kurs immer noch bei 0.04 USD hängt!

RDOC stellt sich neu auf und ist jetzt der einzig verbliebene Anbieter in diesem Bereich!

Wichtig ist, dass Imatron in Japan jetzt gut losläuft,
erwarte da News in kurzer Zukunft!

Hoffentlich erfolgt in Frankreich jetzt bald ein
Anschlussdeal, wäre wichtig für die Bewertung
der letzten News!

Irgendwie wäre es gut, wenn sich ein big player an
RDOC beteiligen würde!

panta rhei,

heraklit

[habkeingeld]

@heraklit

wo hast du deine kurse her??
sehe bei RDOC.OB 0,10$ !



ist natürlich nicht befriedigend aber ein guter neuanfang.

gruss

[heraklit]

Hi No Fear,

D´accord, mea culpa, ich war auf den
Pink Sheets, doch RDOC ist ja jetzt
wieder am OTC BB.

Dann muss ich meine Meinung langsam aber doch
bestimmt und sehr sicher revidieren, Volumina
legen auch zu!

Hoffentlich gelingt ihnen der vereinfachte
Zulassungsweg mit der FDA!

Im Oktober gleich 4 Nachrichten, RDOC
is still alive and kicking!

panta rhei,

heraklit

[NoFear]

@heraklit

Nach meinem Wissensstand stehen zwei bekannte Namen mit ISS in Verbindung:
- IBM mit 2.206479 Aktien
(Kaufpreis 1 Cent; Ausübungszeitpunkt im Falle eines Verkaufes: 31.12.2006 siehe vorletzte Nachricht)
- Siemens über "Siemens Finance and Leasing"
Die Firma kauft ROBODOC von ISS und least sie dann an Krankenhäuser.
Auf die Schnelle habe ich eine Nachricht über den ersten entsprechenden ROBODOC-Verkauf an das Krankenhaus
in Itzehoe gefunden.
Zitat:
"We are very delighted with this sale, particularly because it is the first time that Siemens Finance and Leasing will
purchase the ROBODOC(R) System from ISS and lease it to the clinic. We anticipate that more and more clinics
will now use the interesting and flexible financial leasing arrangement offered by Siemens Finance and Leasing,"
commented Dr. Ramesh Trivedi, CEO and President of ISS.
Der Link dazu: http://bigcharts.marketwatch.com/news/articles.asp?guid={19C…

Für die aktuelle Kursabfrage ist bigcharts absolut ungeeignet. Nach meiner Erfahrung bietet die schnellste (kostenlose)
Kursabfrage (für OTC-Werte) barchart.com. Den passenden Link findest du oben im Thread.
Aktueller Stand (19:25 Uhr)
Kurs 0.11 $
Volumen 164800 Shares

Any comments ?

Best invest
NoFear

[heraklit]

Hi NoFear,

http://quote.yahoo.com/q?s=rdoc.ob&d=v1

Ich fass es nich!

+30 % heute auf 0,13 USD!

Ja, kenne die News mit Siemens F&L
aber bisher scheinbar nur ein Deal gelaufen!

Wäre schön, wenn noch was nachkäme!

Wichtig ist für mich auch, dass der direkte Konkurrent
von ISS in der Zwischenzeit in Konkurs gegangen ist,
d.h. das Potential ist nie grösser, hoffe, Trivedi haut
noch ne News zu Imatron raus in Kürze!

Trivedi hat mal bei IBM gearbeitet,
daher läuft die Software und das Betriebssystem
von Robodoc auf IBM Source Code, den IBM damals gegen
Aktien zur Verfügung gestellt hat!!!!

Ich hatte mich mental schon auf Totalverlust eingestellt,
aber wenn es noch ein paar Tage Volume Alerts gibt sehen
wir ISS sehr schnell wieder bei 0.30 USD ohne News!

panta rhei,

heraklit

[habkeingeld]

dort sehe ich 0,14$

der Siemens deal ist aber schon älter werde mal suchen gehen.

gruss

[habkeingeld]

habe das gerade gefundenhttp://www.dgpw.de/editorial.php3?lang=deu

wußte ich noch nicht das der Caspar aus dem Verkehr gezogen wurde



Sehr geehrte Frau Kollegin,
Sehr geehrter Herr Kollege!

Diese Ausgabe unseres Journales Nr. 23 enthält den ersten Teil der
Manuskripte unserer letztjährigen 38. Jahrestagung. Da Herr Prof. Dr.
med. Oestern plant, die Beiträge über computerassistierte Chirurgie
separat herauszugeben, wird mit dem nächsten Journal Nr. 24 die
Publikation aller Manuskripte der 38. Jahrestagung abgeschlossen.





Abschließend noch ein Bericht über ein Stück geradezu aus dem Tollhaus.
Als Antwort der deutschen Industrie auf den OP-Roboter ROBODOC der amerikanischen Firma ISS
für die Hüft- und Knieprothesenimplantation entwickelte und vertrieb die Maquet-Tochter Orto Maquet
den OP-Roboter CASPAR. Aus finanziellen Gründen wurde die Firma Orto Maquet jetzt ohne
vorherige Ankündigung bei den Kunden aufgelöst, den Mitarbeitern gekündigt und allen Anwendern
des CASPARs die Service- und Leasingverträge entgegen allen vertraglichen Abmachungen mit einer
Frist von 5 Tagen gekündigt.( siehe Seite XX).Bei einigen hundert Patienten mussten seit Monaten
geplante Operationen abgesagt werden.
Auch bei noch so kritischer Beurteilung des Roboterverfahrens zeugt dieses Verhalten der Tochter
der bisher renommierten Firma Maquet gegenüber ihren Kunden und damit auch gegenüber den
Patienten von einer in der Medizinindustrie bislang unbekannten Rücksichtslosigkeit. In eine
besonders schwierige Situation sind vor allem die Häuser gekommen, die der intensiven Werbung
von Orto Maquet und letzlich auch der Mutterfirma Maquet vertrauten und den Roboter für einen
7-stelligen Betrag gekauft haben. Um es noch einmal klarzustellen: Unabhängig von der Einstellung
eines jeden Einzelnen pro oder contra Hüft- u. Knieroboter sollte dieses unglaubliche Vorgehen einer
Medizinproduktefirma in Zukunft zu besonderer Vorsicht im Umgang mit ihr raten und bei
gemeinsamen Geschäftsverbindungen auch berücksichtigt werden, damit etwaige Nachahmer auf
diesem Sektor in Zukunft von vornherein abgeschreckt werden.

Ein solches Vorgehen dürfen wir nicht klaglos tolerieren. Schadenersatzklagen werden zwar
zwangsläufig folgen, die prekäre Situation aber nicht retten.

Mit freundlichen kollegialen Grüßen
Ihr

Dr. H. Rudolph

[heraklit]

Hallo zusammen,

bei 0,17 USD!

Allerdings Spread von 0,10
zu 0,17 USD bei 9.000 Stück!

Hoffe, viele Caspar User wechseln zu ISS!

panta rhei,

heraklit

[NoFear]

Weekly news
Today : Quartalszahlen



10QSB: INTEGRATED SURGICAL SYSTEMS INC


FRIDAY, NOVEMBER 09, 2001 8:22 AM
- Edgar Online

10QSB: INTEGRATED SURGICAL SYSTEMS INC

(EDGAR Online via COMTEX) -- Item 2. Management`s Discussion and Analysis

Results of Operations

Net revenue of $2,735,000 for the three months ended September 30, 2001 brings year-to-date 2001 revenue to
$6,761,000, compared to $5,934,000 for the whole of calendar 2000. Revenue for six systems has been recognized
through the third quarter of 2001 (including three in the three months ended September 30, 2001) against four
systems in all of 2000.

Selling, general and administrative ("SG&A" ) expense at $1,004,000 for the three months ended September 30, 2001
is $470,000 lower than for the same period of 2000the result of cost containment efforts. SG&A rose slightly
($23,000) in the third quarter against the second quarter of 2001, as travel expense associated with our marketing
efforts increased. During the first five months of 2000, most European selling expenses were transferred to an
exclusive distributor. However, administrative cost reductions through 2001 led to a favorable SG&A comparison to
year-to-date 2000, despite this offset.

Research and development ("R&D" ) expenses for 2001 are lower than 2000 on a year-to-date basis due to
cost-savings measures undertaken in 2000 in response to lowered sales projections. While the three months ended
September 30, 2001 show a $227,000 increase in R&D expenses over the same period last year, significant
resources were redirected from R&D to product development contracts in the third quarter of 2000, resulting in a
decrease of approximately $492,000 in R&D expense.

Other income for the three month period ended September 30, 2001 included a transportation claim settlement of
approximately $54,000. The other major component of other income, foreign currency exchange gain, was $108,000
as the dollar weakened slightly against European currencies in the third quarter in comparison to the first half of
2001. The major components of 2000 other income on a year-to-date basis were approximately $740,000 of licensing
fees we received under an exclusive distribution agreement which was terminated in May 2000, offset by
approximately $450,000 in foreign currency losses. There were no comparable licensing fees received in 2001, and
foreign exchange losses were approximately $107,000 through the third quarter.

Liquidity

The report of our independent auditors on our 2000 consolidated financial statements included an explanatory
paragraph indicating that there is substantial doubt with respect to the Company`s ability to continue as a going
concern. Since inception, our expenses have exceeded our revenue, and operations have been funded primarily
through the sale of equity securities. We believe, however, that we have begun to generate sales at a level sufficient
to ensure our survival. Although we believe that our plan will be realized, there is no assurance that this will occur.
The consolidated financial statements do not include any adjustments to reflect the uncertainties related to the
recoverability and classification of assets or the amounts and classification of liabilities that may result from our
inability to continue as a going concern.

Our cash balance at September 30, 2001 was $75,000 greater than at end of the third quarter of 2000, and has
increased $195,000 from the balance at December 31, 2000 as systems sales have increased year-over-year.
However, at September 30, 2001, our current liabilities exceeded our current assets, accounts payable contributed
$363,000 to cash flow over the nine month period, and it has been difficult for us to meet our obligations as they
become due.

Inventory provided approximately $882,000 to cash flow during the third quarter of 2001 and $1,759,000 during the
nine months ended September 30, 2001, as systems were shipped from supplies already on hand. Unearned
income, at $3,091,000, represented 53% of the our liabilities at June 30, 2001. Unearned income includes payments
for systems sales on which revenue is not yet recognized, advance payment for service contracts which revenue is
recognized ratably over the period of the contract and deposits on product development contracts. Accounts
receivable have been our largest use of cash, $1,050,000, since December 31, 2000. Receivables have increased
$905,000 from their second quarter 2001 level, as cash for 1.5 systems remained outstanding at the end of the
quarter.

Capital Resources

On October 23, 2001 the OTC Bulletin Board began to offer quotations on our common stock. Between May 24 and
October 22, 2001 quotes were available only through the pink sheets. While we believe that Bulletin Board coverage
will make it easier for our shareholders to trade their common stock, our shares closed at $0.06 on October 31,
making it unlikely that the equity markets will support fundraising activity at our historic level.

We have received proceeds of $742,000 through our Private Equity Line of Credit Agreement from its inception on
November 2, 2000 through October 31, 2001, and through that date have $11,258,000 in additional credit on which to
draw. However, the level of our current share price means that any use of the equity line of credit will cause
significant dilution to our common shareholders.

(c) 1995-2001 Cybernet Data Systems, Inc. All Rights Reserved

Received by Edgar Online Nov 09, 2001

Link: http://bigcharts.marketwatch.com/news/articles.asp?guid={6CD…


First impression :
ISS hat nach 9 Monaten mehr verdient als im gesamten Jahr 2000.
Bis jetzt wurden 6 Systeme verkauft im Vergleich zu 4 Systemen in 2000 (insgesamt).
Die Finanzlage bleibt zwar kritisch, es gibt aber erste positive Tendenzen.
Mit dem Quartalsbericht wird die Wiederaufnahme des Handels der Aktien an der OTC seit dem 23.10.2001 bestätigt.


Any comments ?


Best invest.
NoFear

[heraklit]

Hallo zusammen,

die gehandelten Volumina werden
grösser und der Spread wird kleiner,
also gute Vorzeichen!

Ich warte immer noch auf eine Nachricht
aus Japan, sollte noch diesen Monat
kommen!

panta rhei,

heraklit

[HRDUERR]

Hallo NoFear,

Vielen Dank für den Hinweis, ich habe mich quergelesen.

Die Kündigung von Caspar hat einige Krankenhäuser schon sehr überrascht, war aber aus der Sicht von Maquet sicher sinnvoll. Die Umsätze mit dem System sind nie sonderlich hoch gewesen, es wurde letztlich nur mit bestimmten trickreichen Konditionen in den Markt gebracht, dabei hatte die Firma sicher nie verdient.
Zudem lief die Ausbildung, Entwicklung und der vertrieb sicher nicht optimal um das hier einmal eher vorsichtig zu formulieren.
Seitens der allgemeinen Haltung bzgl. Roboter hat sich nicht viel verändert, mein Thread von damals:

http://members.tripod.de/hrduerr/rdoc.rtf

hat immer noch Gültigkeit.

Neu sind allerdings eine Reihe von Konkurrenzentwicklungen auf dem Gebiet der Navigation die Robodoc das Leben noch schwerer machen werden.

Es ist eher ruhig um Robodoc geworden.

Die momentane Kurseuphorie hat mich etwas überrascht. Aber da meine Finger noch von der letzten Verbrennung rauchen, warte ich doch lieber erst etwas ab.

Auch die FDA-Zulassung sehe ich noch zurückhaltend. Man muß erst einmal sehen ob die beteiligten Kliniken die Zahlen schaffen

Ich weiß nicht so genau ob der Link auf das Yahoo Board funktioniert. Es wurde damals als "Einladungsboard" gegründet:

http://clubs.yahoo.com/clubs/integratedsurgicalsystems

Ihr

HRDUERR

[NoFear]

@heraklit

Der Austauschprozess hat bereits vor einiger Zeit begonnen..... ;-)

Erste "Robodoc" löst "Caspar" ab


klinikheute.de -Das Diakoniekrankenhaus Rotenburg (Wümme) ist das erste Krankenhaus in Deutschland, das als
Konsequenz auf die fast fristlose Kündigung der Gewährleistungs- und Nutzungsverträge für den OP-Roboter
"CASPAR" der Firma Orto Marquet (klinikheute.de berichtete) einen "ROBODOC" der amerikanischen Firma ISS
(Integrated Surgical Systems, Inc.) bestellt hat. "Damit gibt es auch weiterhin keine Beeinträchtigung in der Versorgung
meiner Patienten", so Dr. Hans Rudolph, Chefarzt der Klinik für Unfall-, Wiederherstellung-, Gefäß- und Plastische
Chirurgie im Diakoniekrankenhaus. Vor drei Jahren hatte das Diakoniekrankenhaus als erstes Krankenhaus in
Deutschland den damals hochmodernen Roboter "CASPAR" in Dienst gestellt. Viele Patienten wollen sich von dem
sicheren und schonenden Operationsroboter in Rotenburg am Knie oder an der Hüfte operieren lassen. "ROBODOC"
hat den "CASPAR" in technischer Hinsicht überholt. "Zurzeit schulen wir unsere OP-Teams an dem neuen
Operationsroboter. Wir werden Mitte Mai die erste Hüftendoprotheseoperation mit dem neuen Roboter durchführen", so
Hans Rudolph.

2001-05-10 Nachricht

http://www.klinikheute.de/Krankenhausinformationendoc23Ers…



Der Text der englischen Meldung ist etwas ausführlicher.

http://www.hoise.com/vmw/01/articles/vmw/LV-VM-06-01-3.html


Best invest
NoFear

[NoFear]

Today: News Update

1. Neues Patent für ISS


Bone motion tracking system (Assignee -- Integrated Surgical Systems, Inc.)

November 29, 2001 5:59pm

A method of tracking and compensating for bone motion when operating on a bone with a surgical robotic arm, comprising:
registering the surgical robotic arm to the bone with a six degree of freedom position sensor; tracking movements of the bone with the six degree of
freedom position sensor; and updating the registration as the bone moves.

Patent Number: 6322567

Issue Date: 2001 11 27

Inventor(s): Mittelstadt, Brent D.
Cohan, Steven M.
.IGNORE_PARA
If you would like to purchase a copy of this patent, please call MicroPatent at
800-648-6787.


Copyright © 2001 MicroPatent LLC
Link : http://hoovnews.hoovers.com/fp.asp?layout=query_displaynews&…


2. Insider-Trades Update 11.12.2001

Link: http://biz.yahoo.com/t/r/rdoce.html




Best invest
NoFear

[NoFear]

Today: News update


Thursday, January 04, 2001 9:10 a.m.
INTEGRATED SURGICAL SYSTEMS APPOINTS ELLIOT J. SMITH TO BOARD OF DIRECTORS

Link: http://bigcharts.marketwatch.com/quickchart/quickchart.asp?s…


Best invest
NoFear

[heraklit]

Hallo zusammen,


etwas passiert!!!

0.16

Change
+0.05 (+45.45%)

Prev Cls
0.11

Volume
309,000

panta rhei,

heraklit

[heraklit]

Hallo zusammen,

News:

Integrated Surgical Systems Announces ROBODOC(R) Sale To the Government of India
DAVIS, Calif., March 15 /PRNewswire-FirstCall/ -- Integrated Surgical Systems, Inc. (OTC Bulletin Board: RDOC - news), a pioneer in medical robotics and a leader in image-directed, semi-autonomous robotic products for surgical applications, has announced the sale of a ROBODOC® Surgical Assistant System to the government of India. The system was delivered to Army Hospital (R & R), New Delhi, one of India`s most sophisticated medical centers.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000329/SFW037 )
``We are delighted to have the opportunity to introduce robotics technology and the ROBODOC System to the Indian subcontinent,`` commented Ramesh Trivedi, President and CEO of Integrated Surgical Systems. ``India is a fast-growing industrial nation with a population that demands and supports advanced medical care. India therefore represents a substantial business opportunity for ISS,`` Dr. Trivedi continued.

``Introduction to the Indian Subcontinent follows our strong market entry to Japan. As was the case in Japan, selection of the right distributor is critical to the long-term success of our business. Our Indian distributor, Paramount Implex, is just such a distributor,`` said Dr. Trivedi.

Mr. Rajesh Bhatia, Managing Director of Paramount Impex stated, ``We were committed to the technology from our first contact with ISS. The positive response from both the medical and administrative staff of Army Hospital made the project very exciting. We see significant opportunity for the ROBODOC System throughout India and its neighboring countries.``

Integrated Surgical Systems designs, manufactures, sells and services image-directed, computer controlled robotic products for use in orthopaedic and neurosurgical procedures. Our ROBODOC® Surgical Assistant System is the world`s leading robotic system for hip and knee replacement surgery. NeuroMate(TM), our neurosurgery system, is the first robotic technology based system for use in stereotactic brain surgery.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including the timely development and market acceptance of new products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC).

NOTE: ROBODOC® is a registered trademark of Integrated Surgical Systems, Inc. NeuroMate(TM) is a trademark of Integrated Surgical Systems, S.A. www.robodoc.com

SOURCE: Integrated Surgical Systems, Inc.

Trishvedi schafft den Turnaround!

panta rhei,

heraklit

[NoFear]

News Update



Thursday April 11, 2:44 pm Eastern Time

Press Release

SOURCE: Integrated Surgical Systems, Inc.

Integrated Surgical Systems Signs Software Development Agreement With Stryker Japan

DAVIS, Calif., April 11 /PRNewswire-FirstCall/ -- Integrated Surgical Systems, Inc. (OTC Bulletin Board: RDOC - news), a pioneer in medical robotics and a
leader in image-directed, semi-autonomous robotic products for surgical applications, has announced a major agreement to develop ROBODOC® software for the Stryker knee prostheses.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000329/SFW037 )

``The Stryker Corporation is one of the world`s leading suppliers of orthopedic products. ISS already provides software for six Stryker hip and knee prostheses and this additional software will offer orthopedic surgeons another option to help ensure an optimal implant for their patients.

While the agreement is with Stryker, Japan, the software will be made available worldwide,`` commented Dr. Ramesh Trivedi, President & CEO of Integrated Surgical Systems.

Integrated Surgical Systems designs, manufactures, sells and services image-directed, computer controlled robotic products for use in orthopaedic and neurosurgical procedures. Our ROBODOC® Surgical Assistant System is the world`s leading robotic system for hip and knee replacement surgery. NeuroMate(TM), our neurosurgery system, is the first robotic technology based system for use in stereotactic brain surgery.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including the timely development and market acceptance of new products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC).

NOTE: ROBODOC® is a registered trademark of Integrated Surgical Systems, Inc.

NeuroMate(TM) is a trademark of Integrated Surgical Systems, S.A.

SOURCE: Integrated Surgical Systems, Inc.

[NoFear]

News Update



Integrated Surgical Systems, Inc. Files For The Approval With The Japanese Regulatory Agency
To Market The ROBODOC(R) Surgical Assistant System (The ROBODOC) In Japan


THURSDAY, OCTOBER 03, 2002 9:02 AM
- Internet Wire

DAVIS, CA, Oct 03, 2002 (INTERNET WIRE via COMTEX) -- Integrated Surgical Systems, Inc. (ISS) (RDOC) , a
pioneer in medical robotics and a leader in image-directed, semi-autonomous robotic products for surgical
applications, announced today that its distributor in Japan, Ktec Corporation and ISS filed on September 30, 2002
with the Ministry of Health, Labor and Welfare (MHLW), the Japanese Regulatory Agency, for the approval to market
the ROBODOC Surgical Assistant System in Japan.

This submission to MHLW was based on the formal clinical trials conducted at Osaka University and Kyowakai
Hospital. The formal clinical protocol called for gathering surgical data including follow-up on at least 60 patients. An
analysis of the data collected indicates that the results meet the requirements of the study as established by
MHLW.

"It is hard to project accurately when the authorities will grant the approval but it is reasonable to expect it within a
year" stated Dr. Ramesh C. Trivedi, President & CEO of Integrated Surgical Systems, Inc. "We are excited about
reaching this milestone as Japan represents the second largest market opportunity for the ROBODOC System"
added Dr. Trivedi.

Integrated Surgical Systems designs, manufactures, sells and services image-directed, computer controlled robotic
products for use in orthopaedic and neurosurgical procedures. Our ROBODOC(R) Surgical Assistant System is the
world`s leading robotic system for hip and knee replacement surgery. NeuroMate(TM), our neurosurgery system, is
the first robotic technology based system for use in stereotactic brain surgery.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking
statements that involve risks and uncertainties, including the timely development and market acceptance of new
products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed
from time to time in the company`s filings with the Securities and Exchange Commission (SEC).

ROBODOC(R) is a registered trademark of Integrated Surgical Systems, Inc.

NeuroMate(TM) is a trademark of Integrated Surgical Systems, S.A. www.robodoc.com.

Ramesh C. Trivedi, Ph.D.
President and CEO
Integrated Surgical Systems
530-792-2600
Charles Novak
CFO
Integrated Surgical Systems
530-792-2600



ISS hat einen Fuß in der Tür zum japanischen Markt.
Wenn dann noch das FDA-Approval folgt, who knows .....






Best invest.
NoFear

[NoFear]

News Update:

1. FDA-Approval

Integrated Surgical Systems, Inc. Reaches An Agreement With Dr. Kenneth Krackow And Buffalo General Hospital/Kaleida Health To Be The Third Site For US FDA Mandated Clinical Trials For The ROBODOC Surgical Assistant System (The ROBODOC)
TUESDAY, DECEMBER 03, 2002 8:03 AM


DAVIS, CA, Dec. 03, 2002 (INTERNET WIRE via COMTEX) --

Integrated Surgical Systems, Inc. (ISS) (RDOC) , a pioneer in medical robotics and a leader in image-directed, semi-autonomous robotic products for surgical applications, announces that it has reached an agreement with Buffalo General Hospital/Kaleida Health and Dr. Kenneth Krackow for their participation as the third clinical site in the US FDA mandated Total Hip Arthroplasty (THA) procedure for the ROBODOC System.

Commenting on this agreement, Ramesh Trivedi, President and CEO of ISS, stated, "This is a very important step in our plan to complete the clinical trials as thoroughly and as rapidly as possible. To date, a total of 89 patients have either already undergone the surgeries or are waiting to be operated as a part of the current clinical studies. With other clinical sites on the West Coast, in the Southwest, we were looking for a highly reputable site on the East Coast."

"Dr. Krackow`s familiarity with the ROBODOC system goes back several years. He played a key role in helping ISS develop the Total Knee Arthroplasty procedure for the ROBODOC system, which has been commercially available outside of the USA since 2000. His reputation as the premier orthopedic surgeon throughout the world, combined with his keen interest in the robotics technology, made him the ideal choice. We are very honored that Dr. Krackow has agreed to participate in this study."

"Ever since I collaborated with ISS in advising and guiding them through the development of ROBODOC TKA procedure, I have been very intrigued and impressed with the robotics technology and its potential in the orthopedic surgeries. Participation in the clinical trials seemed like an excellent way to further involve myself, my staff and the institution with this technology," commented Dr. Krackow.

Integrated Surgical Systems designs, manufactures, sells and services image-directed, computer-controlled robotic products for use in orthopedic and neurosurgical procedures. Our ROBODOC(R) Surgical Assistant System is the world`s leading robotic system for hip and knee replacement surgery. NeuroMate, our neurosurgery system, is the first robotic technology-based system for use in stereotactic brain surgery.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including the timely development and market acceptance of new products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC).

ROBODOC(R) is a registered trademark of Integrated Surgical Systems, Inc.

NeuroMate(TM) is a trademark of Integrated Surgical Systems, S.A.

www.robodoc.com

Ramesh C. Trivedi, Ph.D.
President and CEO
Integrated Surgical Systems
530-792-2600
Charles Novak
CFO
Integrated Surgical Systems
530-792-2600

Copyright 2002 Internet Wire, All rights reserved

http://bigcharts.marketwatch.com/news/articles.asp?guid={987…




2. Germany
hier: Berufsgenossenschaftliche Unfallklinik Frankfurt am Main
Frankfurt am Main, 15. August 2002

...
High-Tech-Medizin in Form eines OP-Roboters zog 1994 in den Klinikalltag ein. Prof. Dr. med. Börner war weltweit der erste Chirurg, der in klinischer Routine den sogenannten Robodoc® verwendete, um einem Patienten eine Hüftprothese einzusetzen. Inzwischen sind in der Berufsgenossenschaftlichen Unfallklinik, die zu den führenden Unfallkliniken Deutschlands zählt, über 5.500 Patienten computerunterstützt an der Hüfte operiert worden. Damit verfügen Prof. Börner und sein Team über die weltweit größte Erfahrung in diesem Bereich. Seit 1999 stehen der Unfallklinik nunmehr drei Robodoc® zur Verfügung. Gäste aus der ganzen Welt kommen immer wieder in die Unfallklinik, um sich über diese Technologie zu informieren. In Japan, Korea, Taiwan, USA, Frankreich, Österreich, Schweiz und Italien werden heute Patienten mit Hilfe von Robodoc® operiert.

Eine neue Indikation kam im Jahre 2000 hinzu. Vor zwei Jahren implantierte Prof. Börner einem Patienten mit Hilfe des Robodoc® ein neues Kniegelenk. Dies war ebenfalls eine Weltpremiere.

Auch im OP-Saal der Neurochirurgie hat ein Roboter Einzug gehalten. Im Sommer 2001 wurde erstmals ein neurochirurgischer Roboter - der NeuroMate® - bei einer Gehirnoperation eingesetzt. Bei einem unfallverletzten Patienten wurde über ein acht Millimeter großes Bohrloch die Hirnblutung ausgeräumt.
....

http://www.bgu-frankfurt.de/themadesmonats/themadesmonats_au…







Best invest
NoFear

[NoFear]

News Update

Today: Market entry in Korea


Integrated Surgical Systems, Inc. Receives Official Approval From KFDA to Market the
ROBODOC(R) Surgical Assistant System (the ROBODOC) in Korea


MONDAY, JANUARY 27, 2003 7:35 AM
- Internet Wire

DAVIS, CA, Jan. 27, 2003 (INTERNET WIRE via COMTEX) -- Integrated Surgical Systems, Inc. (ISS) (OTC BB:
RDOC), a pioneer in medical robotics and a leader in image-directed, semi-autonomous robotic products for surgical
applications, announces that it has received official approval from KFDA to market its ROBODOC Surgical Assistant
System in Korea. KFDA is the governmental regulatory body in Korea that reviews a petition for approval after it
receives all necessary documentation and data.

Commenting on this approval, Dr. Ramesh Trivedi, President and CEO of ISS, stated, "This is a big milestone for ISS
to have accomplished. Korea represents a substantial market, second only to Japan (excluding China) in Asia,
although the rapidly growing market of India is catching up.

"Our Korean distributor, ShinHan Systek, has done an excellent job in shepparding the approval process through the
KFDA agency. Working with ShinHan Systek, ISS expects the sales in Korea will grow rapidly this year and the
years to follow," added Dr. Trivedi.

Integrated Surgical Systems designs, manufactures, sells and services image-directed, computer controlled robotic
products for use in orthopedic and neurosurgical procedures. Our ROBODOC(R) Surgical Assistant System is the
world`s leading robotic system for hip and knee replacement surgery. NeuroMate(TM), our neurosurgery system, is
the first robotic technology based system for use in stereotactic brain surgery.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking
statements that involve risks and uncertainties, including the timely development and market acceptance of new
products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed
from time to time in the company`s filings with the Securities and Exchange Commission (SEC).

ROBODOC(R) is a registered trademark of Integrated Surgical Systems, Inc.

NeuroMate(TM) is a trademark of Integrated Surgical Systems, S.A.

www.robodoc.com. Multimedia available: http://www1.iwire.com/iwire/iwprd?id=050543

Ramesh C. Trivedi, Ph.D.
President and CEO
Integrated Surgical Systems
530-792-2600
Charles Novak
CFO
Integrated Surgical Systems
530-792-2600


Copyright 2003 Internet Wire, All rights reserved.

http://bigcharts.marketwatch.com/news/articles.asp?guid={1CA…


Best invest
NoFear